TipRanks
Advertisement
Advertisement
KHTRF Earnings this Week: How Will it Perform?
PremiumPre-EarningsKHTRF Earnings this Week: How Will it Perform?
2M ago
Analyst Lifts Knight Therapeutics Price Target to $12 on Strong Outperformance and Upgraded 2026 Outlook, Reiterates Buy Rating
Premium
Ratings
Analyst Lifts Knight Therapeutics Price Target to $12 on Strong Outperformance and Upgraded 2026 Outlook, Reiterates Buy Rating
5M ago
Knight Therapeutics price target raised to C$9.50 from C$8.50 at RBC Capital
Premium
The Fly
Knight Therapeutics price target raised to C$9.50 from C$8.50 at RBC Capital
5M ago
Knight Therapeutics sees FY26 revenue C$490M-C$510M
PremiumThe FlyKnight Therapeutics sees FY26 revenue C$490M-C$510M
7M ago
Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
Premium
The Fly
Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year
7M ago
Knight Therapeutics sumbits supplemental MINJUVI application  to ANMAT, COFEPRIS
Premium
The Fly
Knight Therapeutics sumbits supplemental MINJUVI application to ANMAT, COFEPRIS
7M ago
Knight Therapeutics Reports Record Revenues Amid Challenges
PremiumCompany AnnouncementsKnight Therapeutics Reports Record Revenues Amid Challenges
11M ago
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
Premium
Company Announcements
Knight Therapeutics Reports Record Q3 Revenues and Raises Guidance
11M ago
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
Premium
Company Announcements
Knight Therapeutics Achieves Record-High Revenues in Q3 2025
11M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―